Litcius/Paper detail

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire F. Verschraegen, Ram Thapa, Matthew N. Mills, Khaled Dibs, Casey Liveringhouse, Jeffery S. Russell, Jimmy J. Caudell, Ahmad A. Tarhini, Joseph Markowitz, Kari Kendra, Richard C. Wu, Dung‐Tsa Chen, Anders Berglund, Lauren Michael, Mia Aoki, Min-Hsuan Wang, Imène Hamaidi, Pingyan Cheng, Janis V. de la Iglesia, Robbert J Slebos, Christine H. Chung, Todd C. Knepper, Carlos Moran Segura, Jonathan V. Nguyen, Bradford A. Perez, Trevor Rose, Louis B. Harrison, Jane L. Messina, Vernon K. Sondak, Kenneth Y. Tsai, Nikhil I. Khushalani, Andrew S. Brohl

2022The Lancet134 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabIpilimumabMedicineMerkel cell carcinomaOncologyInternal medicineRadiation therapyMerkel cellResponse Evaluation Criteria in Solid TumorsMelanomaCancerCarcinomaPhases of clinical researchClinical trialImmunotherapyCancer researchPolyomavirus and related diseasesBacteriophages and microbial interactionsMultiple Sclerosis Research Studies